News
Norgine gets first EU approval for WHIM syndrome therapy
Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
News
Chiesi signs $1.9bn deal to buy KalVista and its HAE drug
Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
News
AZ will invest £300m in UK, says PM Keir Starmer
AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
News
First-quarter sales strength buoys new GSK CEO Miels
GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.
News
GSK eyes October FDA verdict on chronic hep B drug
GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
